The IgA Nephropathy Landscape Has Experienced Rapid Changes Over Past Two Years with Increased Use of SGLT2 Inhibitors and Tarpeyo (Calliditas); More Change on The Way with Filspari (Travere) Launch, According to Spherix Global Insights

Posted on by

Spherix Global Insights announces the release of its third annual US IgAN patient chart audit showing major shifts in IgAN patient treatments, with additional audits in the EU5, China, and Japan coming soon. EXTON, Pa., March 15, 2023 /PRNewswire/ — Focus on glomerular diseases has…